p107 is a suppressor of retinoblastoma development in pRb-deficient mice

  1. Els Robanus-Maandag1,
  2. Marleen Dekker2,
  3. Martin van der Valk1,
  4. Maria-Luisa Carrozza1,3,
  5. Jean-Claude Jeanny4,
  6. Jan-Hermen Dannenberg2,
  7. Anton Berns1, and
  8. Hein te Riele2,5
  1. 1Division of Molecular Genetics and 2Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 4Institut National de la Santé et de la Recherche Médicale (INSERM) U450, Affiliée Centre National de la Recherche Scientifique (CNRS), Paris, France

Abstract

Hemizygosity for the retinoblastoma gene RB in man strongly predisposes to retinoblastoma. In the mouse, however,Rb hemizygosity leaves the retina normal, whereas inRb −/− chimeras pRb-deficient retinoblasts undergo apoptosis. To test whether concomitant inactivation of the Rb-related gene p107 is required to unleash the oncogenic potential of pRb deficiency in the mouse retina, we inactivated both Rb and p107 by homologous recombination in embryonic stem cells and generated chimeric mice. Retinoblastomas were found in five out of seven adult pRb/p107-deficient chimeras. The retinal tumors showed amacrine cell differentiation, and therefore originated from cells committed to the inner but not the outer nuclear layer. Retinal lesions were already observed at embryonic day 17.5. At this stage, the primitive nuclear layer exhibited severe dysplasia, including rosette-like arrangements, and apoptosis. These findings provide formal proof for the role of loss of Rb in retinoblastoma development in the mouse and the first in vivo evidence that p107 can exert a tumor suppressor function.

Keywords

Footnotes

  • 3 Present address: Instituto di Neurofisiologia del Consiglio Nazionale Ricerche, Pisa, Italy.

  • 5 Corresponding author.

  • E-MAIL hriele{at}nki.nl; FAX 31 205121954.

    • Received February 20, 1998.
    • Accepted April 3, 1998.
| Table of Contents

Life Science Alliance